A5051730519- Cancer Treatment and Pharmacology
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer, Lipids, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Eicosanoids and Hypertension Pharmacology
- Inflammatory mediators and NSAID effects
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Advances in Oncology and Radiotherapy
- Esophageal Cancer Research and Treatment
- Brain Metastases and Treatment
- Vascular Tumors and Angiosarcomas
- Lung Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Ovarian cancer diagnosis and treatment
- Nanoplatforms for cancer theranostics
- COVID-19 and healthcare impacts
- Palliative Care and End-of-Life Issues
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
Fortis Hospital
2013-2021
Tata Memorial Hospital
2020
Homi Bhabha National Institute
2020
AMRI Hospitals
2012-2018
General Hospital of Shenyang Military Region
2017
Orchid Pharma (India)
2013-2015
Fortis Healthcare
2012
Abstract Background: In HER2 over-expressing breast cancer cells, the protein can be cleaved by a metalloproteinase, ADAM10. While extracellular domain (ECD) of is released into serum, truncated receptor fragment, termed p95, remains in tumor cell membrane as constitutively active tyrosine kinase. Previous studies have shown that presence p95 cells associated with poor clinical outcomes patients metastatic positive and it was recently p95+ are resistant to trastuzumab-based therapy....
IntroductionThere is evidence of under-representation women in leadership roles and publications oncology. However, there little knowledge about their perceptions professional environment, unique challenges opportunities compared with male counterparts. The problem more prominent lower-income middle-income countries like India merits exploration.Materials methodsA survey, 'Exploratory Study on the Challenges Female Oncologists India', was conducted among oncology professionals. We included...
Hereditary breast and ovarian cancer (HBOC) syndrome is primarily characterized by mutations in the
302 Background: Paclitaxel protein-bound particles nab-paclitaxel plus gemcitabine is rapidly becoming the standard of care for patients with metastatic adenocarcinoma pancreas (mPCa). Preclinical and clinical studies beta-blockers NSAIDs show a benefit these drugs in pancreatic cancer. The aim this study was to evaluate impact co-administration beta blocker propranolol (P) selective COX-2 inhibitor etodolac (E) on survival mPCa receiving GemNab as care. PE presumed target adrenergic...
Cancers of the liver are one commonest cancers that occur in world, which is hepatocellular carcinoma (HCC). It considered to be 5th cancer world. In areas endemic for hepatitis B and C, it extremely common. Unfortunately, India an zone B, there has been no comprehensive analyzed data HCC. Incidence HCC occurs at two peaks, a young age between 40 55 years another above 60 years. Eighty per cent all HCCs occurring with cirrhosis background 60% these cases positive carriers. Symptoms...
7589 Background: Bavituximab, a novel chimeric IgG1 monoclonal antibody which targets the membrane phospholipid, phosphatidylserine complexed with β2-glycoprotein I on tumor vasculature, was tested in combination paclitaxel and carboplatin multicenter open label, phase II trial to examine clinical response rate safety adults (n = 49) untreated locally advanced or metastatic non-small cell lung cancer. Methods: Subjects received intravenous administration of weekly doses 3 mg/kg bavituximab...
Abstract Breast cancer is a public health challenge globally as well in India. Improving outcome and cure requires appropriate biomarker testing to assign risk plan treatment. Because it documented that significant ethnic geographical variations biological genetic features exist worldwide, such biomarkers need be validated approved by authorities the region where these are intended used. The use of western guidelines, for Caucasian population, can lead inappropriate overtreatment or...
e18059 Background: Systemic inflammatory response, a characteristic of disease progression in patients with advanced cancer, manifests clinically as cachexia. There currently are no FDA approved treatments for cancer Beta-adrenergic antagonists and NSAIDs reduce the level cytokines, catecholamines, acute phase proteins, may attenuate systemic inflammation associated clinical manifestations. Methods: A total 59 subjects were deemed eligible this multicenter, randomized, open-label controlled...
390 Background: Propranolol and etodolac (designated VT-122) target the adrenergic prostaglandin stress systems activated in HCC. These stress-induced are proposed to induce changes tumor microenvironment immune system leading promotion tolerance. In a separate study, administration of VT-122 prior sorafenib showed an increase median overall survival (OS) 21 months when is administered before compared 10 OS for alone. The aim current study was evaluate effect administering at least 30 days...
e13010 Background: Recurrent Glioblastoma is associated with poor prognosis despite treatment.Treatment options are limited. One of the novel methods delivering Temozolomide to use metronomic dosing which also has anti angiogenic properties, beside cytotoxic properties. Preclinical and clinical studies beta-blockers NSAIDs.Propranolol etodolac (PE) well known drugs that function by blocking adrenergic prostaglandin signaling pathways.Their ability inhibit cancer progression metastasis may be...
1069 Background: PICN is a novel, solvent- and protein-free, 100-110 nm particle formulation of paclitaxel stabilized with polymer lipids using Nanotecton Technology. We compared the safety efficacy at two different doses versus albumin-stabilized nanoparticle in 3-weekly schedule subjects MBC. Methods: In this randomized, controlled non-inferiority trial,180 aged18-65 years, MBC, ECOG performance status ≤ 2, estimated survival ≥ 12 weeks adequate organ function, were enrolled randomly...
e16575 Background: Ovarian Cancer isangiogenically driven cancer; use of anti-angiogenic drugs in Platinum Resistance can inhibit growth cell line as well vivo improves survival. Anti-angiogenesis is accepted method therapy for Cancer. Temozolomide continuous low dose administration, targets tumor associated endothelial cells, thereby causing shrinkage tumor. The metronomic also has a higher safety profile than normal dosing. Cyclophosphamide known to be strong drug and an Option Care...
In the year 1918, there was influenza pandemic, wherein India had largest number of cases (10–20 million) among all countries and highest case fatality ratio (4.39%) worldwide.[1] The total magnitude estimated deaths globally 50–100 million. A mathematic model predicted that if similar severity pandemic would have repeated in 2004, mortality toll world over been 62 million, with a trend as past, nearly 14.8 million were alone.[2], [3]
e13005 Background: Glioblastoma is a extremely difficult disease to treat and recurrences are high. Salvage treatment of limited value. This remains an unmet need in oncology. Methods: Since 2003 2012, 32 patients recurrent glioblastoma, post radiotherapy (concomitant with Temozolamide, followed by adjuvant Temozolamide) were taken. above the age 65years 9 it was partially resected. Patients randomized 2 groups, Arm A - metronomic therapy temozolamide B combined propranolol (eccentric...
Response evaluation criteria in solid tumors (RECIST) are a method used to evaluate and document the response cancer treatment tumors. The availability of new class immuneoncology drugs has resulted need modify RECIST methodology. first leadership immuno-oncology network (LION) master course brought together experts oncology immuno-oncology. Six questions were put their opinion, supporting evidence, experience discussed arrive at practical consensus recommendation. n this nascent field,...
Esophageal cancer continues to remain a global problem. The majority of patients with advanced and/or metastatic disease will have limited survival, which has essentially remained unchanged over the past 20 years. dawn immunotherapy resurgence brought hope in lives many lung and other solid tumors. emerging data for esophageal also indicates benefit selected patients. We summarize current available this review.